Our understanding of the mechanisms of cell transformations in cancer driver genes is key to developing more effective cancer detection methods and therapeutic approaches. Test your knowledge of cancer genes and the treatments that target them.
References
- Nahta R, Hung M-C, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64:2343-2346. doi:10.1158/0008-5472.can-03-3856
- Lu X, Li Y, Li Y, et al. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2023;23:1117. doi:10.1186/s12885-023-11600-z
- Du X, Shao Y, Qin HF, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer. 2018;9:423-430. doi:10.1111/1759-7714.12613
- Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464. doi:10.1056/NEJMoa1614359
- Florent L, Saby C, Slimano F, Morjani H. BRAF V600-mutated metastatic melanoma and targeted therapy resistance: an update of the current knowledge. Cancers (Basel). 2023;15:2607. doi:10.3390/cancers15092607